Agreement - December 21, 2016
BioInvent announce collaboration and license agreement with Pfizer
BioInvent International has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer to develop antibodies targeting tumour-associated myeloid cells. Under the terms of the deal, Pfizer will pay BioInvent approximately $10 million in early payments, including an upfront payment, early research funding, and a $6 million equity investment in new shares of […]
Global report - October 21, 2016
Pfizer retracts articles by researcher who has left the company
A senior principal scientist for Pfizer, oncology researcher Min-Jean Yin, has departed the company and five cancer research papers in which she had a hand in crafting have since been retracted due to questionable data. This was found by Leonid Schneider, a Germany-based science writer and he posted it on his For Better Science site […]
Acquisition - August 25, 2016
AZ sells antibiotics business to Pfizer
AstraZeneca has announced that it has entered into an agreement with Pfizer to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US. Under the terms of the agreement, Pfizer will make an upfront payment to AstraZeneca of $550 million upon completion and a further […]
Global report - August 23, 2016
Pfizer to acquire Medivation
Pfizer and Medivation has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have […]
Pharma Business - April 29, 2016
Sobi signs agreement with Pfizer
Swedish Orphan Biovitrum (Sobi) has extended the existing manufacturing agreement with Pfizer for the drug substance for ReFacto AF/XYNTHA until December 31, 2023. The drug substance will continue to be manufactured in Sobi’s GMP biologics facility in Stockholm. In addition, Sobi has decided to move production of Kineret drug substance to Pfizer’s manufacturing site in […]
Global report - April 6, 2016
Pfizer and Allergan terminate $160bn merger
Pfizer and Allergan have terminated their $160bn merger, blaming a crack-down this week on tax inversions deal by the US Treasury Department for scuppering what would have marked the largest-ever healthcare acquisition, reports The Telegraph. Tax avoidance schemes such as inversion deals, in which US companies move their legal addresses overseas to take advantage of lower tax rates, have long been a thorn in the […]
